Fig. 3From: Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort studyMost recent treatment episode: Unadjusted probability of remaining on treatment. Wilcoxon p-value < 0.0001. Note: sample size is reduced since extending the gap period changes the definition of an episode (e.g., distinct episodes with the same drug based on a 15-day gap may become a single episode and is excluded if the episode begins before June 25, 2020)Back to article page